AMPH

MKT CAP $1.1BP/E 15.4DIV YIELD —FCF YIELD 13.80%REV TTM $730M +1.0%NET INCOME $78.5M −41.7%NET CASH $183.3M52W 16.87 – 29.40SEC XBRL · TTM TO Invalid Date

How AMPH rewrote its risk factors

10-K ITEM 1A · FY2024 → FY2025

Text kept

80%

of sentences unchanged

Added

122

new sentences

Dropped

116

sentences removed

Length

+361

words, now 38,926

New in FY2025

The principal factors and uncertainties that make investing in our company risky include, among others: ● our success depends on our ability to develop and/or acquire and commercialize additional pharmaceutical products; ● our BAQSIMI ® , Primatene MIST ® , glucagon, epinephrine, and lidocaine, products collectively represent a significant portion of our net revenues; if the sales volume or pricing of these products decline, or if we are unable to satisfy market demand for these products, this could have a material adverse effect on our business, financial position and results of operations; ● our actual financial and operating results could differ materially from any expectations or guidance provided by us concerning future results; ● our success depends on the integrity of our supply chain, including multiple single source suppliers, and reliance on a third party for the manufacture of BAQSIMI ® the disruption of which could negatively impact our business; ● our ability to develop new products and additional revenue streams depends upon a variety of factors including being able to invest ongoing revenue and borrow funds or raise additional capital when needed; ● we face significant competition in the pharmaceutical industry with respect to both our proprietary and generic drugs, which may result in others developing or commercializing products before or more successfully than we do, which could significantly limit our growth and materially and adversely affect our financial results; ● health care providers may not be receptive to our products, particularly those that incorporate our proprietary drug delivery platforms; ● sales of our products may be adversely affected by the continuing consolidation of our customer base; ● we depend upon our key personnel, the loss of whom could adversely affect our operations.
Our BAQSIMI ® , Primatene MIST ® , glucagon, epinephrine, and lidocaine products collectively represent a significant portion of our net revenues.
If the sales volume or pricing of these products decline, or if we are unable to satisfy market demand for these products, they could have a material adverse effect on our business, financial position and results of operations. Sales from our BAQSIMI ® product that we acquired in June 2023 represented 26%, 20%, and 8% of our total net revenues for the years ended December 31, 2025, 2024, and 2023, respectively.
Sales from our Primatene MIST ® product represented 15%, 14%, and 14% of our total net revenues for the years ended December 31, 2025, 2024, and 2023, respectively.
Sales from our glucagon product, represented 10%, 15% and 18% of our total net revenues for the years ended December 31, 2025, 2024, and 2023, respectively.
Sales from our epinephrine product represented 10%, 13%, and 13% of our total net revenues for the years ended December 31, 2025, 2024, and 2023, respectively.
Sales from our lidocaine products represented 8%, 8%, and 9% of our total net revenues for the years ended December 31, 2025, 2024, and 2023, respectively.
We have experienced declining revenue from glucagon and some of our other existing products in the past.
If the sales volume or pricing of glucagon and epinephrine multi-dose vial continues to decline, or if the sales volume or pricing of lidocaine declines, or if we are unable to satisfy market demand for these products, our business, financial position and results of operations could be materially and adversely affected, and the market value of our common stock could decline.
For example, our glucagon and our epinephrine multi-dose vial products continue to see increased competition in the market, which could result in declining per unit prices as well as lower market share due to intense pricing competition in the pharmaceutical industry.
We have experienced significant declines in the per unit pricing and gross margins attributable to our glucagon product since its commercial launch.
Our BAQSIMI ® , Primatene MIST ® , glucagon, epinephrine, and lidocaine, products could be rendered obsolete or negatively impacted by numerous factors, many of which are beyond our control, including: ● decreasing average sales prices; ● development by others of new pharmaceutical products that are more effective than ours; ● entrance of new competitors into our markets; ● loss of key relationships with suppliers, group purchasing organizations or end-user customers; ● manufacturing or supply interruptions; ● increase in material input costs; ● changes in the prescribing practices of physicians; ● changes in third-party reimbursement practices; ● implementation of prescription drug cost containment measures; ● changes in applicable FDA, health care, and environmental law; ● product liability claims; and ● product recalls or safety alerts.
Our research and development expense was $85.8 million, $73.9 million, and $73.7 million for the years ended December 31, 2025, 2024, and 2023, respectively.
Our success depends on the integrity of our supply chain, including multiple single source suppliers, and reliance on a third party for the manufacture of BAQSIMI ® , the disruption of which could negatively impact our business.
We depend on CMOs and suppliers to perform manufacturing activities effectively and on a timely basis for our API and drug products.
These third parties are independent entities subject to their own unique operational and financial risks that are out of our control.
For example, in 2023, our API supplier for medroxyprogesterone discontinued making the active ingredient, which resulted in a halt in sales of the product after the third quarter of 2023.
Additionally, any failure by us to forecast demand for, or to maintain an adequate supply of, the raw material and finished product could result in an interruption in the supply of certain products and a decline in sales of that product.
Underutilization of our manufacturing capacity could negatively impact our gross margins.
For example, a significant portion of our manufacturing capacity in our facility in Éragny-sur-Epte, France is utilized for the manufacturing of insulin API for MannKind, and, until recently, a significant portion of our manufacturing capacity in Rancho Cucamonga was utilized for the manufacture of enoxaparin.
Mannkind will not be purchasing RHI for at least the next two years as they are in the process of qualifying our upgraded RHI, which uses our internally produced inclusion bodies made at AFP.
If an increase in supply outpaces the increase in market demand, or if demand decreases, such as a further reduction in sales of insulin API for MannKind, the resulting oversupply could adversely impact our sales and result in the underutilization of our manufacturing capacity, high inventory levels, changes in revenue mix and rapid price erosion, which would lower our margins and adversely impact our financial results.
It is possible that developments by our competitors will make our products or technologies noncompetitive or obsolete. Our current and future indebtedness has and may continue to adversely affect our operating results and cash flows.
The acquisition of BAQSIMI ® was financed with proceeds of the senior secured term loan, or the Wells Fargo Term Loan, provided by the syndicated credit agreement, or the Credit Agreement, by and among the Company, certain subsidiaries of the Company, as guarantors, certain lenders, and Wells Fargo Bank, National Association, or Wells Fargo, as Administrative Agent (in such capacity, Agent), Swing line Lender and L/C Issuer.
Finally, if the court’s decision is adverse to the ANDA applicant, the ANDA approval will be delayed until the challenged patent expires, and the applicant will not be granted the 180-day marketing exclusivity. Accordingly, our revenues and future profitability are dependent, in large part, upon our ability or the ability of our development partners to file ANDAs with the FDA timely and effectively or to enter into contractual relationships with other parties that have obtained marketing exclusivity.
For example, glucagon is also marketed by Viatris, Inc., Cipla Limited, Lupin Pharmaceuticals, Inc., and others also either market or plan to market a generic version of glucagon.
Other companies may have received FDA approval of glucagon but have not launched the product, while other companies may have filed ANDAs for glucagon with the FDA.
The presence of these current and prospective competitive products has had, and may continue to have, an adverse effect on our market share, revenue and gross profit from our glucagon product.
Since the commercial launch of our glucagon product, we have experienced significant declines in sales volume, per unit pricing and gross margins attributable to this product.
If the market for any of our reference brand products significantly declines, sales or potential sales of our generic and biosimilar products and product candidates may suffer and our business would be materially impacted.
As new products are approved that compete with the reference proprietary product to our generic products and generic or biosimilar product candidates, sales of the reference brand products may be significantly and adversely impacted and may render the reference brand product obsolete.
Sales to three of these customers for the years ended December 31, 2025, 2024, and 2023, respectively, accounted for approximately 65%, 64%, and 60% of our total net revenues, respectively.
Our business may be adversely affected by challenging macroeconomic conditions globally. General conditions in the global economy and in the global financial markets could adversely affect our results of operations, and the overall demand for our products.
Downturns in economic conditions and recessions, including inflationary pressures and changes in interest rates could continue to decrease spending and adversely affect demand for our products and harm our business and results of operations.
A severe or prolonged economic downturn or political disruption could result in a variety of risks to our business, including weakened demand for our products and our ability to raise additional capital when needed on acceptable terms, if at all.
A weak or declining economy or political disruption could also strain our manufacturers or suppliers, possibly resulting in supply disruption, or cause our customers to delay making payments for our products.
Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the political or economic climate and financial market conditions could adversely impact our business.
We may be exposed to product liability claims and may not be able to obtain or maintain adequate product liability insurance. Our business exposes us to potential product liability risks, which are inherent in the testing, manufacturing, marketing and sale of pharmaceutical products.
For example, in 2023 we acquired BAQSIMI ® from Eli Lilly & Company.
As of December 31, 2025, the value of our goodwill and intangible assets net of accumulated amortization was $566.0 million.

and 82 more.

Gone since FY2024

The principal factors and uncertainties that make investing in our company risky include, among others: ● our success depends on our ability to develop and/or acquire and commercialize additional pharmaceutical products; ● our BAQSIMI ® , Primatene MIST ® , glucagon, epinephrine, lidocaine, phytonadione, and enoxaparin products collectively represent a significant portion of our net revenues; if the sales volume or pricing of these products decline, or if we are unable to satisfy market demand for these products, this could have a material adverse effect on our business, financial position and results of operations; ● our actual financial and operating results could differ materially from any expectations or guidance provided by us concerning future results; ● our success depends on the integrity of our supply chain, including multiple single source suppliers, the disruption of which could negatively impact our business; ● our ability to develop new products and additional revenue streams depends upon a variety of factors including being able to invest ongoing revenue and borrow funds or raise additional capital when needed; ● we face significant competition in the pharmaceutical industry with respect to both our proprietary and generic drugs, which may result in others developing or commercializing products before or more successfully than we do, which could significantly limit our growth and materially and adversely affect our financial results; ● health care providers may not be receptive to our products, particularly those that incorporate our proprietary drug delivery platforms; ● sales of our products may be adversely affected by the continuing consolidation of our customer base; ● we depend upon our key personnel, the loss of whom could adversely affect our operations.
For example, as a result of environmental concerns over the use of chlorofluorocarbons, or CFCs, the FDA, issued a final rule in 2009, that required the phase-out of the CFC formulation of our Primatene MIST ® product by the end of 2011.
As a result, in order to resume selling Primatene MIST ® we had to develop a formulation of the product that uses hydrofluoroalkane, or HFA, as the propellant, and obtain FDA approval for the modified product, which took a significant amount of time and was not re-launched until December 2018.
For example, we filed an ANDA, for our enoxaparin product in March 2003, but FDA approval was not granted until September 2011 due to delays caused largely by the FDA’s requirement that we perform immunogenicity studies and the receipt of an FDA warning letter and FDA Import Alert by the supplier of the starting material for our enoxaparin product.
Following FDA approval, we became involved in litigation with Momenta Pharmaceuticals, Inc. and Sandoz Inc., which further delayed the commercial launch of our enoxaparin product until January 2012.
Our BAQSIMI ® , Primatene MIST ® , glucagon, epinephrine, lidocaine, phytonadione, and enoxaparin products collectively represent a significant portion of our net revenues.
If the sales volume or pricing of these products decline, or if we are unable to satisfy market demand for these products, they could have a material adverse effect on our business, financial position and results of operations. Sales from our BAQSIMI ® product that we acquired in June 2023 represented 20% and 8% of our total net revenues for the years ended December 31, 2024 and 2023, respectively.
Sales from our Primatene MIST ® product represented 14%, 14%, and 17% of our total net revenues for the years ended December 31, 2024, 2023, and 2022, respectively.
Sales from our glucagon product, represented 15%, 18% and 11% of our total net revenues for the years ended December 31, 2024, 2023 and 2022, respectively.
Sales from our epinephrine product represented 13%, 13%, and 15% of our total net revenues for the years ended December 31, 2024, 2023, and 2022, respectively.
Sales from our lidocaine products represented 8%, 9%, and 11% of our total net revenues for the years ended December 31, 2024, 2023, and 2022, respectively.
Sales from our phytonadione product represented 6%, 7%, and 10% of our total net revenues for the years ended December 31, 2024, 2023, and 2022, respectively, and sales of our enoxaparin product represented 3%, 5%, and 7% of our total net revenues for the years ended December 31, 2024, 2023, and 2022, respectively.
We have experienced declining revenue from enoxaparin and some of our other existing products in the past.
If the sales volume or pricing of enoxaparin continues to decline, or if the sales volume or pricing of lidocaine and phytonadione declines, or if we are unable to satisfy market demand for these products, our business, financial position and results of operations could be materially and adversely affected, and the market value of our common stock could decline.
For example, our enoxaparin product continues to see increased competition in the market, which could result in declining per unit prices as well as lower market share due to intense pricing competition in the pharmaceutical industry.
We have experienced significant declines in the per unit pricing and gross margins attributable to our enoxaparin product since its commercial launch.
Our BAQSIMI ® , Primatene MIST ® , glucagon, epinephrine, lidocaine, phytonadione, and enoxaparin products could be rendered obsolete or negatively impacted by numerous factors, many of which are beyond our control, including: ● decreasing average sales prices; ● development by others of new pharmaceutical products that are more effective than ours; ● entrance of new competitors into our markets; ● loss of key relationships with suppliers, group purchasing organizations or end-user customers; ● manufacturing or supply interruptions; ● increase in material input costs; ● changes in the prescribing practices of physicians; ● changes in third-party reimbursement practices; ● implementation of prescription drug cost containment measures; ● changes in applicable FDA, health care, and environmental law; ● product liability claims; and ● product recalls or safety alerts.
Our research and development expense was $73.9 million, $73.7 million, and $74.8 million for the years ended December 31, 2024, 2023, and 2022, respectively.
Our success depends on the integrity of our supply chain, including multiple single source suppliers, the disruption of which could negatively impact our business.
For example, in 2009, we purchased heparin USP as the starting material for producing our enoxaparin product exclusively from a single source supplier and, in 2009, this supplier received a warning letter from the FDA and was the subject of an FDA Import Alert.
The resulting shortage of heparin USP resulted in significant delays to the FDA approval process for our enoxaparin product.
There are no guarantees our supplier will not receive warning letters in the future or that we will be able to replace this single source supplier with an alternate supplier on a commercially reasonable and timely basis, or at all, to prevent a shortage of heparin USP.
Subsequently, we received FDA approval to make heparin USP from crude heparin using processes at our ANP and IMS facilities.
In 2023, our API supplier for medroxyprogesterone discontinued making the active ingredient, which resulted in a halt in sales of the product after the third quarter of 2023.
Additionally, any failure by us to forecast demand for, or to maintain an adequate supply of, the raw material and finished product could result in an interruption in the supply of certain products and a decline in sales of that product. Underutilization of our manufacturing capacity could negatively impact our gross margins.
For example, a significant portion of our manufacturing capacity in our facility in Éragny-sur-Epte, France is utilized for the manufacturing of insulin API for MannKind, and a significant portion of our manufacturing capacity in Rancho Cucamonga is utilized for the manufacture of enoxaparin.
Mannkind will not be purchasing RHI for the next two years as they are in the process of qualifying our upgraded RHI, which uses our internally produced inclusion bodies made at AFP. If an increase in supply outpaces the increase in market demand, or if demand decreases, such as a further reduction in sales of insulin API for MannKind, the resulting oversupply could adversely impact our sales and result in the underutilization of our manufacturing capacity, high inventory levels, changes in revenue mix and rapid price erosion, which would lower our margins and adversely impact our financial results.
It is possible that developments by our competitors will make our products or technologies noncompetitive or obsolete. Our current and future indebtedness has and may continue to adversely affect our operating results and cash flows. The acquisition of BAQSIMI ® was financed with proceeds of the senior secured term loan, or the Wells Fargo Term Loan, provided by the syndicated credit agreement, or the Credit Agreement, by and among the Company, certain subsidiaries of the Company, as guarantors, certain lenders, and Wells Fargo Bank, National Association, or Wells Fargo, as Administrative Agent (in such capacity, Agent), Swing line Lender and L/C Issuer.
Finally, if the court’s decision is adverse to the ANDA applicant, the ANDA approval will be delayed until the challenged patent expires, and the applicant will not be granted the 180-day marketing exclusivity.
Accordingly, our revenues and future profitability are dependent, in large part, upon our ability or the ability of our development partners to file ANDAs with the FDA timely and effectively or to enter into contractual relationships with other parties that have obtained marketing exclusivity.
For example, enoxaparin is currently marketed by Sanofi, under the brand name Lovenox ® .
Sanofi also markets its authorized generic enoxaparin product through its subsidiary, Winthrop.
Fresenius Kabi USA, Apotex Corp., Zydus Pharmaceuticals USA Inc., Sandoz, Meithael Pharmaceuticals, Inc., and others also either market or plan to market a generic version of enoxaparin.
Other companies may have received FDA approval of enoxaparin but have not launched the product, while other companies have filed ANDAs for enoxaparin with the FDA.
The presence of these current and prospective competitive products has had, and may continue to have, an adverse effect on our market share, revenue and gross profit from our enoxaparin product.
Since the commercial launch of our enoxaparin product, we have experienced significant declines in sales volume, per unit pricing and gross margins attributable to this product.
For example, as mentioned above, Sanofi currently markets an authorized generic enoxaparin product through its subsidiary, Winthrop.
This is a significant source of competition for us because brand companies do not face any regulatory barriers to introducing authorized generics of their products.
If the market for a reference brand product, such as Lovenox ® , significantly declines, sales or potential sales of our generic and biosimilar products and product candidates may suffer and our business would be materially impacted.
As new products are approved that compete with the reference proprietary product to our generic products and generic or biosimilar product candidates, such as Lovenox ® , which is the reference brand product for our enoxaparin product, sales of the reference brand products may be significantly and adversely impacted and may render the reference brand product obsolete.

and 76 more.

Sentence-level comparison of Item 1A in the two most recent 10-Ks (FY2024 ↗, FY2025 ↗). A reworded sentence counts as one dropped and one added, so heavy edits read as low “kept”. Headings and page furniture are stripped; nothing is summarised by a model.

Watch AMPH. Know when insiders buy.

One email the day a filing lands. Free.